OBJECTIVE： To study the pharmacokinetic characteristics of Recombinant hirudin enteric-coated capsule by single and multiple administration in Beagle dogs. METHODS： 12 Beagle dogs were divided into single ig group and single iv group by random control method， 6 in each group. Recombinant hirudin 0.2 mg/kg was intragastrically administrated or intravenously injected， blood sample was collected； after 2 weeks of cleaning， 12 dogs were intragastrically administrated recombinant hirudin 0.2   mg/kg， for 7 d. Sample blood was collected， referred to multiple ig group. Recombinant hirudin concentration in plasma was determined by enzyme-linked immunosorbent assay， and pharmacokinetic parameters were calculated by DAS 2.0 software. RESULTS： The results showed that pharmacokinetics by ig and iv recombinant hirudin in Beagle dogs fitted to two-compartment model， absolute bioavailability of ig Recombinant hirudin enteric-coated capsule was （14.908±1.868）％； the pharmacokinetic parameters in single ig group and multiple ig group were tpeak of （2.105±0.243）， （3.000±0.000） h， t1/2β of （8.660±2.965）， （14.870±2.710） h， cmax of （10.700±0.872）， （12.05±1.587） ng/mL， AUC0-1 440 min of （55.250±4.386）， （58.978±6.002） ng·h/mL， without statistical significances in two groups（P＞0.05）. CONCLUSIONS： The ig Recombinant hirudin enteric-coated capsule can be absorbed into the blood to a certain extent. There is no accumulation for ig Recombinant hirudin enteric-coated capsule for several days， and it dose not change the pharmacokinetic characteristics.